| Maui Medical Group Inc | |
|
2180 Main St, Wailuku, HI 96793-1625 | |
| (808) 242-6464 | |
| (808) 242-4292 |
| Full Name | Maui Medical Group Inc |
|---|---|
| Type | Facility |
| Speciality | Internal Medicine |
| Location | 2180 Main St, Wailuku, Hawaii |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215963970 | NPI | - | NPPES |
| Provider Name | Ryan S Fusato |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1578580296 PECOS PAC ID: 6709784960 Enrollment ID: I20031224000023 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Kimberly M Kowalski |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1538107453 PECOS PAC ID: 0143111690 Enrollment ID: I20040323001379 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Zora Bulatovic |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1629001227 PECOS PAC ID: 4486697612 Enrollment ID: I20050608000306 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Nolan P Arruda |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1043242209 PECOS PAC ID: 9436180841 Enrollment ID: I20050825000647 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Deborah Mathias |
|---|---|
| Provider Type | Practitioner - General Practice |
| Provider Identifiers | NPI Number: 1336163237 PECOS PAC ID: 4183647837 Enrollment ID: I20060109000367 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Lorene K Siaw |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1417002510 PECOS PAC ID: 4587760905 Enrollment ID: I20070501000693 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Alan D Odonovan |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1619915311 PECOS PAC ID: 7911097084 Enrollment ID: I20071213000583 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Constantin Novoselsky |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1861650764 PECOS PAC ID: 7618038654 Enrollment ID: I20081209000251 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Karla Kn Kurokawa |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1730333725 PECOS PAC ID: 7517020167 Enrollment ID: I20090108000511 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Don Halouska |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1558348359 PECOS PAC ID: 5496651242 Enrollment ID: I20090527000332 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Deyaa Mounir |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1366427908 PECOS PAC ID: 4789614215 Enrollment ID: I20091105000228 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | William Fagan |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1417976143 PECOS PAC ID: 7315081742 Enrollment ID: I20100223000237 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Roxanne E. Bhattacharya |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1295768893 PECOS PAC ID: 5294860524 Enrollment ID: I20100311000930 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Matthew Ho |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1912923103 PECOS PAC ID: 3476688110 Enrollment ID: I20100319000054 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Diane Nagasaka |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1144256603 PECOS PAC ID: 8426183096 Enrollment ID: I20100322000297 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Daniel B Garcia |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1689699449 PECOS PAC ID: 9133257173 Enrollment ID: I20100512000277 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | George Powell |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1265446785 PECOS PAC ID: 3971634312 Enrollment ID: I20100628000992 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | William Mitchell |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1972527877 PECOS PAC ID: 6204967524 Enrollment ID: I20100701000147 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Guy Hirayama |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1679594980 PECOS PAC ID: 2668368713 Enrollment ID: I20100707000579 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Anne Biedel |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1114944832 PECOS PAC ID: 8022035799 Enrollment ID: I20100824000226 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Melody Jayne |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1689973554 PECOS PAC ID: 8628029501 Enrollment ID: I20110630000470 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Lana Wilkinson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1861457012 PECOS PAC ID: 5991731788 Enrollment ID: I20110727000531 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Rosemarie I Foronda |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1154346914 PECOS PAC ID: 6406029347 Enrollment ID: I20111109000470 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Turgut Berkmen |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1346232683 PECOS PAC ID: 0446262414 Enrollment ID: I20121116000350 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Ellecia Cook |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1831422906 PECOS PAC ID: 2365685005 Enrollment ID: I20130828001007 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Khaled Walid Hamzeh |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1861682056 PECOS PAC ID: 8921253337 Enrollment ID: I20140620000734 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Ernest J Lee |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1578645990 PECOS PAC ID: 4183882327 Enrollment ID: I20140805000578 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Coral W Yap |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1902191828 PECOS PAC ID: 9436377397 Enrollment ID: I20140905002533 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Alexander A Divin |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1437445855 PECOS PAC ID: 7012136153 Enrollment ID: I20140922002247 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Anna Hom |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1063421733 PECOS PAC ID: 9032158316 Enrollment ID: I20141107001286 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Sherelle L Lum |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588069074 PECOS PAC ID: 4183949449 Enrollment ID: I20150207000081 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Derek R Illastron |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1790949956 PECOS PAC ID: 8921176264 Enrollment ID: I20160504002708 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Kelly Runge |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1528442639 PECOS PAC ID: 9032408380 Enrollment ID: I20160510001634 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Marc Rosenthal |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1144290339 PECOS PAC ID: 5496733941 Enrollment ID: I20160525001724 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Timothy Berney |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1548239239 PECOS PAC ID: 4880720663 Enrollment ID: I20170127000610 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Giedre Karakalpakis |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1477824399 PECOS PAC ID: 1658508247 Enrollment ID: I20171101001843 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Shannon Leigh Mccormick |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1053832329 PECOS PAC ID: 0345506606 Enrollment ID: I20171102002461 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Michelle Ogues |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1548686223 PECOS PAC ID: 1456617729 Enrollment ID: I20171102002908 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Ioannis Karakalpakis |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1033418264 PECOS PAC ID: 6305018540 Enrollment ID: I20171102002922 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Tanya Takatani-apo |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1821516618 PECOS PAC ID: 6406117571 Enrollment ID: I20180306002280 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Nicholas Alexander Atkinson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194295170 PECOS PAC ID: 4688914310 Enrollment ID: I20190315002326 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Heidi Kyoko Garcia |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1437620515 PECOS PAC ID: 4486994480 Enrollment ID: I20190328001146 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Marirose Calderon |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1063837680 PECOS PAC ID: 2466718663 Enrollment ID: I20190805003345 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Aaron Milstone |
|---|---|
| Provider Type | Practitioner - Sleep Medicine |
| Provider Identifiers | NPI Number: 1134211550 PECOS PAC ID: 7315001039 Enrollment ID: I20190820000866 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Heidi Denton |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1982086385 PECOS PAC ID: 8123334174 Enrollment ID: I20191013000010 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Marcelino Yera-paez |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1679868855 PECOS PAC ID: 5092953745 Enrollment ID: I20200121000386 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Jalin K.a. Finai |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1710502331 PECOS PAC ID: 1153743042 Enrollment ID: I20200623001363 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Cecilia Velarde Harrington |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1538555206 PECOS PAC ID: 8224345673 Enrollment ID: I20201019000009 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Andrew Sumida |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1740712397 PECOS PAC ID: 6507286192 Enrollment ID: I20201021000221 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Janet Lee |
|---|---|
| Provider Type | Practitioner - Interventional Pain Management |
| Provider Identifiers | NPI Number: 1386063634 PECOS PAC ID: 1153548797 Enrollment ID: I20210721003340 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Rina Kojima Rousek |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1235596560 PECOS PAC ID: 0547568313 Enrollment ID: I20210820001412 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Rowena Nikki Baysa |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1205409018 PECOS PAC ID: 8820493018 Enrollment ID: I20210826001188 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Robert Loree |
|---|---|
| Provider Type | Practitioner - Interventional Radiology |
| Provider Identifiers | NPI Number: 1720220783 PECOS PAC ID: 2668691577 Enrollment ID: I20210831002576 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Amy Tang Hou |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1417396490 PECOS PAC ID: 5890191712 Enrollment ID: I20210901001007 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Imola K Osapay |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1558616094 PECOS PAC ID: 9335467422 Enrollment ID: I20211111001439 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Jeuniece R Sampson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1174016372 PECOS PAC ID: 3173870029 Enrollment ID: I20211116001714 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Nicole Nazemi |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1962906610 PECOS PAC ID: 3678964954 Enrollment ID: I20211221000905 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Brooke E Raidmae |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1093260291 PECOS PAC ID: 2365721479 Enrollment ID: I20220523002048 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Ralph Salib-o Domingo |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528706207 PECOS PAC ID: 5698153542 Enrollment ID: I20220604000184 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Alexei Zhadkevich |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1760642268 PECOS PAC ID: 5698078533 Enrollment ID: I20220719001347 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Chandler R Riem |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1003587536 PECOS PAC ID: 7113309212 Enrollment ID: I20220805002775 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Anne Baker Bealer |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1679929962 PECOS PAC ID: 5193007482 Enrollment ID: I20221006002648 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Jolly Anne Lorenzo Uclaray |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1922762574 PECOS PAC ID: 8224406517 Enrollment ID: I20221117000650 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Melissa Diane Patao |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1134791742 PECOS PAC ID: 4688071707 Enrollment ID: I20221213001804 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Amy Rhine |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1205020013 PECOS PAC ID: 1355439316 Enrollment ID: I20230116000943 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Theresa Duggan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1770950669 PECOS PAC ID: 8426365719 Enrollment ID: I20230421002349 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Katherine Ann Rice |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1881210391 PECOS PAC ID: 9436576642 Enrollment ID: I20230717001742 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Bradley Neuman |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1053622548 PECOS PAC ID: 8820354806 Enrollment ID: I20230817001821 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Joanna Marie Plumb |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114536448 PECOS PAC ID: 7315354644 Enrollment ID: I20230831004322 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Provider Name | Megin John |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1215228648 PECOS PAC ID: 7214198886 Enrollment ID: I20230926000851 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Maui Medical Group Inc 2180 Main St, Wailuku, HI 96793-1625 Ph: (808) 242-6464 | Maui Medical Group Inc 2180 Main St, Wailuku, HI 96793-1625 Ph: (808) 242-6464 |
News Archive
BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.
Following the closure of nearly 100 women's health clinics across the United States from 2010 to 2013, fewer women were screened for cervical cancer, more women were diagnosed with advanced stages of the disease and mortality rates rose.
Neurotechnology, a provider of high-precision biometric identification technologies, has released new versions of the company's core product Software Development Kits (SDKs) for fingerprint, face, iris and multi-biometric identification. The latest SDK versions, VeriFinger 6.1, VeriLook 3.3, VeriEye 2.1 and MegaMatcher 3.0, provide enhanced interoperability, reliability and ease-of-maintenance over previous versions.
A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.
› Verified 9 days ago